【个人简介】

田新贵，男，博士，副研究员，博士生导师，广州市高层次人才，广东省医学会感染病学分会青委会委员。工作经历：2017年至今广州医科大学呼吸疾病全国重点实验室副教授，2018-2019年加拿大萨斯喀彻温大学（VIDO-InterVac）博士后，2004-2010年广州市妇女儿童医疗中心中心实验室技术员。发表论文70余篇，获授权发明专利21项，指导研究生3名、博士后3名、本科生多名。

招生专业：生物学、基础医学和内科学（学术学位）。ORCiD：https://orcid.org/0000-0001-9761-6677。Email：xgtian@gzhmu.edu.cn。

【研究方向】

呼吸道病毒的致病机制、疫苗、中和抗体、抗病毒药物和动物模型。

【科研项目】

1. 国家自然科学基金面上项目（32370155）：CD46和DSG2双受体在人B组腺病毒感染与致病中的协同作用和机制研究。2024/01- 2027/12，50万，在研，主持。

2. 国家自然科学基金面上项目（82072264）：人B组腺病毒中和抗体的作用机制研究。55万，2021/01-2024/12，在研，主持。

3. 广东省自然科学基金面上项目（2023A1515010589）：一株抗人B组腺病毒广谱中和单抗的人源化改造及评价动物模型的建立。 10万，2023/01-2025/12，在研，主持。

4. 广州医科大学学生创新能力提升计划项目（2023-178）：一种人7型腺病毒感染小鼠模型及应用。2万，2024/3-2026/3，在研，指导教师。

5. 国家自然科学基金面上项目（31570163）：人B组腺病毒纤毛蛋白与DSG2受体亲和力的差异及其对病毒致病力的影响研究。62万，2016/01-2019/12，已结题，主持。

6. 科技部国家重点研发计划生物安全关键技术研发专项（2018YFC1200100）：突发急性和烈性传染病临床救治关键技术研究。34万，2018/08-2021/06，已结题，项目骨干。

7. 广东省自然科学基金面上项目（2021A1515011071）：人7型腺病毒十二面体病毒样颗粒的制备及其免疫原性研究。10万，2021/1-2023/12，已结题，主持。

8. 广州市科技计划项目（市院校联合项目）（202102010364）：基于腺病毒病毒样颗粒展示平台的2019新型冠状病毒疫苗候选研究。25万，2020/11-2022/10，已结题，主持。

【代表性论文及著作】

1. Zhang Q, Zhou Z, Fan Y, Liu T, Guo Y, Li X, Liu W, Zhou L, Yang Y, Mo C, Chen Y, Liao X, Zhou R, Ding Z, Tian X. 2024. Higher affinities of fibers with cell receptors increase the infection capacity and virulence of human adenovirus type 7 and type 55 compared to type 3. Microbiol Spectr 12:e01090-23.

2. Xingui Tian, Xiao Li, Shuyan Qiu, Rong Zhou, Wenkuan Liu. 2023. Abnormal liver function in children hospitalized with acute respiratory infection of adenoviruses: a retrospective study. Virol Sin. 38(5):735-740.

3. Mo C, Li X, Wu Q, Fan Y, Liu D, Zhu Y, Yang Y, Liao X, Zhou Z, Zhou L, Li Q, Zhang Q, Liu W, Zhou R, Tian X. 2023. SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses. Vaccine. 9:S0264-410X(23)01156-8.

4. Liling Zhou, Chuncong Mo, Yujie Yang, Zhichao Zhou, Aiping You, Ye Fan, Wenkuan Liu, Xiao Li, Rong Zhou and Xingui Tian. 2023. Characterization and application of a series of monoclonal antibodies against SARS‐CoV‐2 nucleocapsid protein. Journal of Medical Virology 95(1):e28225.

5. Liu W, Zhang L, Cai Y, Zhang Q, Chen D, Qiu S, Wang Y, Xu D, Gu S, Li X, Dai J, Liu Q, Zhou R and Tian X. 2022. Human Adenovirus Subtype 21a Isolates From Children With Severe Lower Respiratory Illness in China. Front. Microbiol. 13:924172.

6. Jiang Z, Zhang Y, Lin H, Cheng Q, Lu X, Liu W, Zhou R, Zhong B and Tian X. A 10-Day-Old Murine Model of Coxsackievirus A6 Infection for the Evaluation of Vaccines and Antiviral Drugs. Frontiers in Immunology. 2021;12(1731).

7. Xingui Tian, Chuncong Mo, Liling Zhou, Yujie Yang, Zhichao Zhou, Aiping You, Ye Fan, Wenkuan Liu, Xiao Li, Rong Zhou. Epitope mapping of severe acute respiratory syndrome-related coronavirus nucleocapsid protein with a rabbit monoclonal antibody. Virus Res. 2021. 300: 198445

8. Xiao Li, Zhichao Zhou, Wenkuan Liu, Ye Fan, Yinzhu Luo, Kangtian Li, Zhenxia Zheng, Xingui Tian, Rong Zhou. Chinese tree shrew: a permissive model for in vitro and in vivo replication of human adenovirus species B. Emerging Microbes & Infections.2021. 10(1): 424-438

9. Tian XG, Fan Y, Wang CB, Liu ZW, Liu WK, Xu Y, Mo CC, You AP, Li X, Rong X, Zhou R. Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, China. Virologica Sinica.2021 Jun;36(3):373-381.

10. Xingui Tian, Shelby Landreth, Yao Lu, Kannupriya Pandey, Yan Zhou. A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice. J Virol. 2021 Jan 13;95(3):e02154-20.

11. Shi-ying Chen, Wenkuan Liu, Yun Xu, Shuyan Qiu, Yong Chen, Xingui Tian, Rong Zhou. Epidemiology and Genetic Variabilities of Human Adenovirus Type 55 Reveal Relative Genome Stability Across Time and Geographic Space in China. Front. Microbiol. 2020 Dec 2;11:606195.

12. Xingui Tian, Ye Fan, Zhenwei Liu, Ling Zhang, Jiayi Liao, Zhichao Zhou, Xiao Li, Tiantian Liu, Wenkuan Liu, Hongling Qiu and Rong Zhou. 2018. Broadly neutralizing monoclonal antibodies against human adenovirus types 55, 14p, 7, and 11 generated with recombinant type 11 fiber knob. Emerg Microbes Infect, 7(1):206.

13. Xingui Tian, Hongling Qiu, Zhichao Zhou, Shouli Wang, Ye Fan, Xiao Li, Ruiai Chu, Haitao Li, Rong Zhou, Hui Wang. 2018. Identification of a Critical and Conformational Neutralizing Epitope in Human Adenovirus Type 4 Hexon. J Virol, 92(2):e01643-17.

14. Tian X, Jiang Z, Fan Y, Qiu S, Zhang L, Li X, Zhou Z, Liu T, Ma Q, Lu X, Zhong B, and Zhou R. 2018. A tetravalent vaccine comprising hexon-chimeric adenoviruses elicits balanced protective immunity against human adenovirus types 3, 7, 14 and 55. Antiviral Res 154: 17-25.

15. Tian X. , Ma Q. , Jiang Z., Huang J., Liu Q., Lu X., Luo Q., and Zhou R., 2015. Identification and Application of Neutralizing Epitopes of Human Adenovirus Type 55 Hexon Protein. Viruses 7, 5632-5642.

16. Tian X. , Liu M. , Su X., Jiang Z., Ma Q., Liao X., Li X., Zhou Z., Li C., and Zhou R., 2015. Mapping the epitope of neutralizing monoclonal antibodies against human adenovirus type 3. Virus Res 208, 66-72.

17. Tian X. , Su X. , Xue C., Li X., Zhou Z., and Zhou R., 2014. Antigenic variability among two subtypes of human adenovirus serotype 7. Virus Genes 49, 22-29.

18. Tian X. , Su X. , Li X., Li H., Li T., Zhou Z., Zhong T., and Zhou R., 2012. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon. PLoS One 7, e41381.

19. Qiu H. , Li X. , Tian X., Zhou Z., Xing K., Li H., Tang N., Liu W., Bai P., and Zhou R., 2012. Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions. J Virol 86, 7964-7975.

20. Jing Dai, Duo Xu, Chao Yang, Huan Wang, Dehui Chen, Zhengshi Lin, Shuyan Qiu, Li Zhang, Xiao Li, Xingui Tian, Qian Liu, Yujun Cui, Rong Zhou and Wenkuan Liu. 2023. Severe pneumonia and pathogenic damage in human airway epithelium caused by Coxsackievirus B4. Emerging Microbes & Infections 12(2). 2261560.

21. Ruilin Zheng, Danyang Chen, Jingyao Su, Jia Lai, Chenyang Wang, Haitian Chen, Zhihui Ning, Xia Liu, Xingui Tian, Yinghua Li and Bing Zhu. 2023. Inhibition of HAdV-14 induced apoptosis by selenocystine through ROS-mediated PARP and p53 signaling pathways. Journal of Trace Elements in Medicine and Biology 79(127213.

22. Shuyan Qiu, Duo Xu, Jing Dai, Li Zhang, Xingui Tian, Xiao Li, Dehui Chen, Rong Zhou and Wenkuan Liu. 2023. Improving the efficiency and biosafety of respiratory syncytial virus identification using a nucleic acid extraction‐free reagent. Journal of Medical Virology 95(1). e28287.

23. Yi Chen, Tao Lin, Chang-Bing Wang, Wan-Li Liang, Guang-Wan Lian, Mark Zanin, Sook-San Wong, Xin-Gui Tian, Jia-Yu Zhong, Ying-Ying Zhang, Jia-Hui Xie, Ling-Ling Zheng, Fei-Yan Chen, Run Dang, Ming-Qi Zhao, Yi-Yu Yang, Rong Zhou and Bing Zhu. 2022. Human adenovirus (HAdV) infection in children with acute respiratory tract infections in Guangzhou, China, 2010–2021: a molecular epidemiology study. World journal of pediatrics : WJP 18(8). 545-552.

24. 田新贵，杨玉洁，周志超，周荣. 抗人4型腺病毒中和抗体及其制备方法和应用: 中国专利CN202311568702.5[P]. 2023-11-23. 已授权.

25. 田新贵，杨玉洁，周荣. 抗人腺病毒中和抗体及其制备方法和应用: 中国专利CN202311172288.6[P]. 2023-09-12. 已授权.

26. 田新贵，周李灵，杨玉洁，莫纯聪，周荣. 融合蛋白、病毒样颗粒以及疫苗: 中国专利CN202310058949.6[P]. 2023-01-13. 已授权.